CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaShannon L. Maude, Stephan A. Grupp|Blood|2015Cited by 718
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletionLeila Amini, Mohamed Abou‐El‐Enein, Sara Silbert et al.|Nature Reviews Clinical Oncology|2022Cited by 324
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionNathan Singh, Marco Ruella, Yong Gu Lee et al.|Cancer Discovery|2020Cited by 297
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemiaKaren L. Bride, David T. Teachey, Richard Aplenc et al.|Blood|2018Cited by 226
Cdk Inhibition in Human Cells Compromises Chk1 Function and Activates a DNA Damage ResponseShannon L. Maude, Greg H. Enders|Cancer Research|2005Cited by 58